Paid Clinical Trials Chattanooga
Discover 129 paid clinical trials in Chattanooga, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Study with Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure with Severely Reduced Ejection FractionStudy with Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure with Severely Reduced Ejection Fraction
Sponsor:
Cytokinetics
Location:
Code:
NCT06736574
Conditions
Heart Failure
Heart Failure with Reduced Ejection Fraction
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Omecamtiv Mecarbil (OM)
Placebo
A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic DuodenitisA Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
Sponsor:
Regeneron Pharmaceuticals
Location:
Code:
NCT05831176
Conditions
Eosinophilic Gastritis
Eosinophilic Duodenitis
Eosinophilic Gastrointestinal Disease
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Dupilumab Dose 1
Dupilumab Dose 2
Matching Placebo
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaSelinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Sponsor:
Karyopharm Therapeutics Inc
Location:
Code:
NCT05611931
Conditions
Endometrial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Selinexor
Matching Placebo for selinexor
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
Sponsor:
Gilead Sciences
Location:
Code:
NCT06060665
Conditions
Primary Biliary Cholangitis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Seladelpar 10 mg
Placebo
Avexitide for Treatment of Post-Bariatric HypoglycemiaAvexitide for Treatment of Post-Bariatric Hypoglycemia
Sponsor:
Amylyx Pharmaceuticals Inc.
Location:
Code:
NCT06747468
Conditions
Post Bariatric Hypoglycemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Avexitide
Placebo
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT05878769
Conditions
Chronic Obstructive Pulmonary Disease
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
Astegolimab
Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryAnticoagulation in ICH Survivors for Stroke Prevention and Recovery
Sponsor:
Yale University
Location:
Code:
NCT03907046
Conditions
Intracerebral Hemorrhage
Atrial Fibrillation
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Apixaban
Aspirin
The CONFORM Pivotal TrialThe CONFORM Pivotal Trial
Sponsor:
Conformal Medical, Inc
Location:
Code:
NCT05147792
Conditions
Atrial Fibrillation
Stroke
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CLAAS
WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung CancerSafety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
Sponsor:
Agennix
Location:
Code:
NCT00706862
Conditions
Non Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Talactoferrin
Placebo
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Sponsor:
Bristol-Myers Squibb
Location:
Code:
NCT05552976
Conditions
Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Mezigdomide
Carfilzomib
Dexamethasone